Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

JAMA Dermatol. 2017 Sep 1;153(9):942-944. doi: 10.1001/jamadermatol.2017.1679.

Authors

Yasuhiro Nakamura¹, Yukiko Teramoto¹, Yuri Asami¹, Taisuke Matsuya¹, Jun-Ichi Adachi², Ryo Nishikawa², Akifumi Yamamoto¹

Affiliations

¹ Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.
² Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan.

PMID: 28678991
DOI: 10.1001/jamadermatol.2017.1679

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antineoplastic Agents, Immunological / therapeutic use
Biopsy
Humans
Male
Melanoma / complications*
Melanoma / diagnosis
Melanoma / secondary
Neoplasm Metastasis
Neoplasm Recurrence, Local
Nivolumab / therapeutic use*
Skin / pathology*
Vitiligo / diagnosis
Vitiligo / drug therapy*
Vitiligo / etiology

Substances

Antineoplastic Agents, Immunological
Nivolumab